Ofichem Header Ofichem Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Eikonizo Therapeutics","sponsor":"McQuade Center for Strategic Research and Development","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The McQuade Center for Strategic Research and Development and Eikonizo Ink Deal to Develop Treatments for Patients with Rare Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2021","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"}]

    Find Clinical Drug Pipeline Developments & Deals by Eikonizo Therapeutics

    Menu

    Eikonizo Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Eikonizo Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              The McQuade Center for Strategic Research and Development and Eikonizo Ink Deal to Develop Treatments for Patients with Rare Diseases

              Details:

              Under the terms of the agreement, MSRD and Eikonizo will collaborate to advance Eikonizo’s HDAC6 inhibitors through preclinical and Phase 1b clinical studies respectively, with the opportunity to expand the collaboration after those studies.

              Lead Product(s): Undisclosed

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: IND Enabling Product Type: Small molecule

              Recipient: McQuade Center for Strategic Research and Development

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration February 09, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
              AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
              Post Enquiry
              POST ENQUIRY